BD SiteRite(TM) 9 Ultrasound System - Clinical Study
← catalyst calendarSponsored by Becton, Dickinson and Company (industry) · BDX — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
149actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-12 | actual | When the study began enrolling |
| Primary completion | 2026-01-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- BD SiteRite 9 for VAD Insertion
Intervention
- Device: BD SiteRite(TM) 9
Primary outcomes
what the primary-completion date above is the date OFPrimary Performance: To provide visualization of the target vessel in which to insert the chosen vascular access device.
measured During the procedure
Primary Performance: To have successful vascular access either by cannulation or blood return.
measured During the procedure
Primary Safety: To determine the incidence of device related adverse events, experienced by patient or user, when using the BD SiteRiteTM 9 Ultrasound System.
measured During the procedure and 15 minutes after the procedure
Permalink · BDX's whole pipeline · Catalyst calendar · Every registered study · What changed